Fresenius SE & Co. KGaA filed Amendment No. 13 to its Schedule 13D on November 13, 2026, disclosing a sale of 13,443,240 ordinary shares of Fresenius Medical Care AG through an accelerated book-building process priced on November 11, 2026.

Key Highlights

  • Shares sold: 13,443,240 ordinary shares of Fresenius Medical Care AG were sold at EUR 39.00 (approximately $43.26) per share pursuant to a pricing agreement dated November 11, 2026.
  • Remaining stake: Following the placement, Fresenius KGaA beneficially owns 53,738,118 shares, representing approximately 20.9% of the company's outstanding voting shares.
  • Share base used: The 20.9% figure is calculated with reference to 257,312,593 shares outstanding as of November 6, 2026, as disclosed by Fresenius Medical Care AG on its website in connection with its ongoing share buyback program.
  • Joint bookrunners: BNP Paribas, BofA Securities Europe SA, Deutsche Bank Aktiengesellschaft, and J.P. Morgan SE acted as joint bookrunners under the Share Purchase Agreement.
  • Lock-up period: Fresenius KGaA agreed not to sell or otherwise transfer additional shares for 90 days beginning November 12, 2026, subject to certain exceptions and the prior written consent of at least two of the joint bookrunners.
  • Expected closing: The Share Placement is expected to close on November 16, 2026, subject to the conditions in the Share Purchase Agreement.
  • Strategic context: According to the filing, Fresenius KGaA is entering into this transaction "as part of its broader portfolio optimization strategy."

Fresenius KGaA Reduces Fresenius Medical Care Stake via Accelerated Book-Build

Fresenius SE & Co. KGaA, a partnership limited by shares organized under German law, disclosed in this Schedule 13D/A that on November 11, 2026, it entered into a Share Purchase Agreement with four joint bookrunners to sell a block of ordinary shares of Fresenius Medical Care AG (NYSE:FMS) through an accelerated book-building process. According to the filing, 13,443,240 shares were sold at a price of EUR 39.00 (approximately $43.26) per share under a pricing agreement executed the same day. The shares were sold in an unregistered offering pursuant to exemptions from registration under the U.S. Securities Act of 1933, as amended.

Following the completion of the Share Placement, Fresenius KGaA reported sole voting and dispositive power over 53,738,118 shares, constituting approximately 20.9% of Fresenius Medical Care AG's outstanding voting shares. The filing notes that Management SE, the general partner of Fresenius KGaA, exercises investment and dispositive power over those shares and may be deemed a beneficial owner of them. All 53,738,118 shares are described as issued, outstanding, and held directly by Fresenius KGaA.

The filing states that Fresenius KGaA "intends to review its investment in the Company on a continuing basis and, depending on market conditions, the trading price of the Shares, legal or regulatory developments and other factors, may from time to time consider or pursue alternatives with respect to such investment." The amendment also updated disclosure on significant indirect holders of Fresenius KGaA's own share capital, citing most recent notifications received from those entities, including BlackRock, Inc. at approximately 5.02% and Harris Associates L.P. at approximately 2.99%, among others.

What Was Disclosed

Fresenius KGaA filed Amendment No. 13 to its Schedule 13D to report the sale of 13,443,240 Fresenius Medical Care AG ordinary shares at EUR 39.00 each on November 11, 2026, reducing its beneficial ownership to 53,738,118 shares, or approximately 20.9% of the outstanding voting shares.